autologous mononuclear stem cell
Cell therapyexperimental
Clinical trial activity
131 trials · 185 clinical orgs · 0 marketing orgs
Phase 1
40
Phase 2
89
Phase 3
25
Phase 4
3
Earliest trial started Oct 1, 1994 (NCT00869284)
Timeline
Indications
Approved for
Studied for
- Amyloidosis · Phase 3
- Amyotrophic Lateral Sclerosis · Phase 2/Phase 3
- Anemia, Sickle Cell · Phase 1
- Angioplasty, Balloon, Coronary · Phase 2
- Anterior Wall Myocardial Infarction · Phase 2
- Atherosclerosis · Phase 2/Phase 3
- Autism Spectrum Disorder · Phase 2
- Autoimmune Diseases · Phase 2/Phase 3
- Brain Neoplasms · Phase 2/Phase 3
- Cardiomyopathies · Phase 1/Phase 2
- Cardiomyopathy, Dilated · Phase 2/Phase 3
- Cardiovascular Diseases · Phase 2
- Cerebral Palsy · Phase 2/Phase 3
- Chronic Limb-Threatening Ischemia · Phase 2
- Churg-Strauss Syndrome · Early Phase 1
- Craniocerebral Trauma · Phase 1/Phase 2
- Diabetes Mellitus, Type 2 · Phase 2/Phase 3
- Ependymoma · Phase 2/Phase 3
- Fanconi Anemia · Phase 1
- Hearing Loss, Sensorineural · Phase 1/Phase 2
- Heart Diseases · Phase 2
- Heart Failure · Phase 2
- Hematopoietic Stem Cell Transplantation · Phase 2
- Hepatitis, Chronic · Phase 2
- Hodgkin Disease · Phase 2
- Huntington Disease · Phase 1/Phase 2
- Immunoglobulin Light-chain Amyloidosis · Phase 2
- Immunoglobulin Light Chains · Phase 2
- Infarction, Middle Cerebral Artery · Phase 2
- Intermittent Claudication · Phase 1
- Leg Ulcer · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Leukemia, Lymphoid · Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 2
- Leukemia, Myeloid, Acute · Phase 4
- Leukemia, Promyelocytic, Acute · Phase 4
- Liver Cirrhosis · Phase 2
- Lymphoma · Phase 2
- Lymphoma, B-Cell · Phase 3
- Lymphoma, Extranodal NK-T-Cell · Phase 3
- Lymphoma, Follicular · Phase 2/Phase 3
- Lymphoma, Large B-Cell, Diffuse · Phase 3
- Lymphoma, Large-Cell, Immunoblastic · Phase 3
- Lymphoma, Mantle-Cell · Phase 2
- Lymphoma, Non-Hodgkin · Phase 3
- Lymphoma, T-Cell · Phase 2
- Medulloblastoma · Phase 2/Phase 3
- Mucositis · Phase 1
- Multiple Myeloma · Phase 4
- Multiple Sclerosis · Phase 1/Phase 2
- Multiple Sclerosis, Relapsing-Remitting · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 2
- Myeloproliferative Disorders · Phase 2
- Myocardial Infarction · Phase 3
- Myocardial Ischemia · Phase 2
- Neoplasms · Phase 2/Phase 3
- Neoplasms, Germ Cell and Embryonal · Phase 2
- Neoplasms, Plasma Cell · Phase 2
- Neuroblastoma · Phase 2
- Osteosarcoma · Phase 2
- Peripheral Arterial Disease · Phase 1
- Plasmacytoma · Phase 2
- Recurrence · Phase 1
- Scleroderma, Systemic · Phase 2/Phase 3
- Sclerosis · Phase 2/Phase 3
- Spinal Cord Injuries · Phase 2
- Stem Cells · Phase 1
- Stem Cell Transplantation · Phase 2
- Stroke · Phase 2
- Testicular Neoplasms · Phase 2
Mechanism of action
- Unspecified targetTissue restoration
tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous bone marrow-derived mononuclear cells
- autologous bone marrow-derived mononuclear stem cells
- autologous bone marrow mononuclear cells
- autologous mononuclear stem cell
- autologous peripheral blood stem cell
- autologous peripheral blood stem cells
- autologous peripheral stem cell
- autologous stem cell
- autologous stem cells
- mononuclear cells
- mononuclear stem cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06629324 | Phase 2 | Oct 15, 2024 | Vinmec International Hospital |
| NCT05808010 | N/A | Jun 7, 2023 | Shandong Provincial Hospital |
| NCT06427642 | N/A | Apr 1, 2022 | Qilu Pharmaceutical Co., Ltd., Shandong University |
| NCT04907526 | Phase 1 | Jun 1, 2021 | Children's Hospital Los Angeles, Mayo Clinic, Ochsner Health System, ReGen Theranostics, Inc., University of Alabama, Birmingham, University of Cincinnati, University of Colorado, University of Minnesota, University of Oklahoma, University of Pennsylvania, University of Toronto |
| NCT04893629 | N/A | May 20, 2021 | Damascus University |
| NCT04849065 | Phase 2 | May 1, 2021 | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia |
| NCT05293873 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2021 | Vinmec International Hospital |
| NCT04620681 | Phase 1/Phase 2 (Phase 2) | Nov 16, 2020 | Food and Drug Administration, University of South Florida |
| NCT04528550 | Phase 2 | Oct 1, 2020 | Second Military Medical University |
| NCT03003728 | Phase 2 | Aug 1, 2017 | Altor Bioscience, Bristol-Myers Squibb, Hoosier Cancer Research Network |
| NCT03030261 | Phase 2 | Jul 1, 2017 | Bristol-Myers Squibb, Celgene, Washington University in St. Louis |
| NCT03019640 | Phase 2 | Jun 1, 2017 | University of Texas at Houston |
| NCT02843074 | Phase 2 | Sep 21, 2016 | Bristol-Myers Squibb, SCRI Development Innovations |
| NCT02923817 | Phase 2 | Sep 1, 2016 | Da Nang Hospital, Kitano Hospital, Translational Research Informatics Center, Kobe, Hyogo, Japan |
| NCT02728271 | Early Phase 1 (Phase 1) | Aug 1, 2016 | University of Pittsburgh |
| NCT02728102 | Phase 2 | Jul 1, 2016 | Blood and Marrow Transplant Clinical Trials Network, Center for International Blood and Marrow Transplant Research, National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Marrow Donor Program |
| NCT05472428 | Phase 1 | Jul 1, 2016 | Vinmec International Hospital |
| NCT02776605 | Phase 2 | Jun 1, 2016 | PETHEMA Foundation |
| NCT02605421 | Phase 2 | Jun 1, 2016 | University of Minnesota |
| NCT02756728 | Phase 1/Phase 2 (Phase 2) | May 1, 2016 | BioInvent International AB, University of Pennsylvania |
Showing 20 of 131 trials
Page 1 / 7
Organizations
Research & Development (185)
185 organizations
Page 1 / 10